SCHEMBL4236380

SCHEMBL4236380

CCCCN1CCC(Oc2ccc(C(=O)Nc3ccc(Cc4ccc(NC(=O)NC(C)C)cc4)cc3)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 8/20 0.47
SLC6A5 Q9Y345 1/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
OPRM1 P35372 2/20 0.43
OPRD1 P41143 2/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 2/20 0.43
ALDH1A1 P00352 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
HSD17B10 Q99714 1/20 0.43
KDM4E B2RXH2 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ADRB2 P07550 2/20 0.42
CHRM2 P08172 1/20 0.42
NAMPT P43490 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4235491 0.93 HRH3 (0.48) HRH3MEN1KMT2AOPRM1OPRD1
SCHEMBL4229358 0.90 HRH3 (0.47) HRH3MEN1KMT2AOPRM1OPRD1
SCHEMBL4238075 0.88 HRH3 (0.44) HRH3MEN1KMT2AOPRM1OPRD1
SCHEMBL4686567 0.85 RAF1 (0.40) HRH3SLC6A5
SCHEMBL4233415 0.85 MCHR1 (0.50) HRH3MEN1KMT2AMAPTALDH1A1
SCHEMBL4231873 0.85 CHRM3 (0.43) HRH3MEN1KMT2AOPRM1OPRD1
SCHEMBL4231991 0.85 PKM (0.45) HRH3SLC6A5MEN1KMT2AOPRM1
SCHEMBL4235464 0.84 MCHR1 (0.44) HRH3TSHRNAMPT
SCHEMBL4236986 0.84 MCHR1 (0.43) HRH3SMN1; SMN2NAMPT
SCHEMBL4232252 0.83 HRH3 (0.42) HRH3MEN1KMT2AOPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R HRH3 210/4885SLC6A5 3347/4885MEN1 2447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.